Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I
Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease
Comparison with Metformin and SGLT2 Inhibitors Metformin: Often a first-line diabetes drug, but less effective for weight loss
Time to event analysis from enrollment was used to assess time from MASH without cirrhosis to compensated cirrhosis, time to the first decompensation event (ascites/complications from ascites, hepatic encephalopathy, variceal bleeding) in patients with MASH compensated cirrhosis, and time to all-cause mortality in each of the 3 sub-cohorts
Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management that works through dual GIP and GLP-1 receptor agonism
The process is straightforward once you understand the steps